T1	Intervention 0 11	Eltrombopag
T2	Intervention 121 132	Eltrombopag
T3	Intervention 139 175	oral thrombopoietin receptor agonist
T4	Intervention 262 288	eltrombopag versus placebo
T5	Intervention 409 427	placebo-controlled
T6	Intervention 672 676	plus
T7	Intervention 680 714	mg eltrombopag or matching placebo
T8	Intervention 1319 1357	response to eltrombopag versus placebo
T9	Intervention 1623 1652	(135 eltrombopag, 62 placebo)
T10	Intervention 1673 1691	in the eltrombopag
T11	Intervention 1855 1873	in the eltrombopag
T12	Intervention 1900 1914	in the placebo
T13	Intervention 2030 2051	receiving eltrombopag
T14	Intervention 2108 2117	receiving
T15	Intervention 2156 2177	receiving eltrombopag
T16	Intervention 2234 2243	receiving
T17	Intervention 2275 2305	patients receiving eltrombopag
T18	Intervention 2354 2362	patients
T19	Intervention 2373 2374	.
T20	Intervention 2375 2404	Nine (7%) eltrombopag-treated
T21	Intervention 2422 2433	(3%) in the
T22	Intervention 2510 2543	and five (4%) eltrombopag-treated
T23	Intervention 2562 2571	allocated
T24	Intervention 2628 2643	patients taking
T25	Intervention 2713 2737	treated with eltrombopag
T26	Intervention 2739 2765	INTERPRETATION Eltrombopag
T27	Intervention 3000 3027	associated with eltrombopag
